GSK3A and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) inhibition activates GSK3α-mediated phosphorylation of PD-L1, which facilitates ARIH1-mediated ubiquitination at K271 and K281, promoting proteasomal degradation [27].